The Nonhuman Primate (NHP) Core seeks to consolidate the NHP experimental objectives of the Consortia for AIDS Vaccine Research (CAVR) in Nonhuman Primates proposal into a single Core composed of highly experienced research personnel. This Core will provide the expertise and technical support required to insure successful completion of the multifaceted and extensive NHP research protocols supporting Project 1 """"""""Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection"""""""", Project 2 - """"""""CMV Vectors and Early Control of Mucosal SIV Challenge"""""""", Project 3 - """"""""Live Attenuated SIV-Mediated Protection Against Mucosal SIV Infection"""""""", Project 4 - """"""""Mechanisms of Antibody Interception of Virus Following SHIV Challenge"""""""" and Project 5 - """"""""Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection"""""""". These projects constitute a collaborative, interactive, and comprehensive investigation of acute mucosal SIV infection and the systematic evaluation of vaccines and which immune responses can block or modulate these early events of SIV infection to prevent infection or disease. The global objective of the Core is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, application of experimental animal procedures, animal observations and data collection necessary to meet the comprehensive investigation objectives of the CAVR.'s To accomplish this, the Core will manage and directly supervise all NHP studies for the CAVR including: 1) animal selection;2) animal housing and general husbandry;3) experimental procedures and clinical management;4) specimen collection and processing;5) necropsy studies;and 6) acquisition and management of animal demographic, physiologic, clinical, and pathologic data.

Public Health Relevance

NHP research is expensive, and requires highly specialized resources and personnel. Consolidation of multiple interactive projects into a integrative multdicipline core had decided advantages in correlation of results, efficient animals handling and speciment process, use of fewer animals and efficient use of animals facility space and resources.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI095985-04
Application #
8704252
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
Okoye, Afam A; Hansen, Scott G; Vaidya, Mukta et al. (2018) Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440
Abbink, Peter; Larocca, Rafael A; Dejnirattisai, Wanwisa et al. (2018) Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nat Med 24:721-723
Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137
Aid, Malika; Abbink, Peter; Larocca, Rafael A et al. (2017) Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169:610-620.e14
Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos et al. (2017) Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9:
Keele, Brandon F; Li, Wenjun; Borducchi, Erica N et al. (2017) Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun 8:15740
Barouch, Dan H; Thomas, Stephen J; Michael, Nelson L (2017) Prospects for a Zika Virus Vaccine. Immunity 46:176-182
Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270
McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81
Tomalka, Jeffrey; Ghneim, Khader; Bhattacharyya, Sanghamitra et al. (2016) The sooner the better: innate immunity as a path toward the HIV cure. Curr Opin Virol 19:85-91

Showing the most recent 10 out of 57 publications